Background: Few studies have assessed the impact of hospice care in patients with
| INTRODUCTION
Primary liver cancers are significant causes of liver-related mortality and resource utilisation worldwide. In the United States (U.S.), liver cancer is predominantly represented by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). [1] [2] [3] [4] HCC is one of the few solid tumours with a rising incidence in the U.S. with the main driver related to the clinical burden of chronic hepatitis C (HCV) and possibly non-alcoholic fatty liver disease. [1] [2] [3] [4] [5] [6] As the HCV population ages, there are great concerns about the potential impact on Medicare resources. [7] [8] [9] One mode of medical care that has shown to improve not only patients' quality of life but also resource utilisation is palliative medicine and hospice care. Palliative care and hospice services have been shown to significantly improve the care of patients with various chronic and critical illnesses and are now considered to be part of standard of care for patients with advanced disease. [10] [11] [12] [13] [14] [15] [16] [17] Two recent studies 18, 19 examined patients with endstage liver disease using data from the National Inpatient Sample (NIS). Both studies found a significant increase in in-patient palliative care consultation over the past decade, and the integration of palliative care services in the care of these patients was associated with lower cost. 20 Of note, both studies limited their study population to patients who received in-patient palliative care consultation during their admission. It is important to note that the increase in the hospice care utilisation among patients with advanced GI cancers is primarily attributed to palliative care consultation. 21 In this context, physicians from other specialties such as gastroenterology, haematology, hospital medicine and primary care services can also participate in this process by determining the need for hospice care without asking for a consultation from a palliative care specialist.
Despite the studies of liver disease and GI cancers, the impact of hospice utilisation among patients with liver cancer has not been fully assessed. We aimed to build on previous studies on the use of palliative care services among patients with end-stage liver disease, by examining the determinants of hospice enrolment among Medicare beneficiaries diagnosed with primary liver cancer, and describing the outcomes on resource utilisation and survival.
| MATERIALS AND METHODS

| Data source
The study cohorts were identified from the Surveillance, Epidemiol- 24 See Figure 1 for detailed information.
| Definitions of outcomes
The following outcomes were assessed as follows: (1 total annual (yearly) hospital charges, total charges for the services utilised by the patient during each hospitalisation for that year were added together, and this represents total annual hospital charges for that year. Also, to determine patients' average annual (yearly) hospital charges, patients' total yearly hospital charges were divided by the total number of hospital discharges for that specific year.
Charges/payments were adjusted to 2009 U.S. dollars using the Consumer Price Index. 25 Reference is as follows: Bureau of Labor (localised, regional, distant and unstaged; see Appendix S1 for definitions of staging), cancer treatment (history of radiation or surgery was coded "Yes" if the patient had the following: radiation before surgery, radiation after surgery, radiation both before and after surgery, intraoperative radiation therapy, intraoperative radiation with other radiation given before or after surgery, sequence unknown, but both surgery and radiation were; and "No" if no history of radiation and/or surgery as defined above).
| Statistical analysis
Pairwise comparisons were performed by hospice enrolment status.
Continuous variables were examined with two-sided t test, and categorical variables were examined with chi-square tests. Logistic regression was used to estimate the odds ratios (ORs) with 95% confidence intervals (CIs) for hospice enrolment. For within one-year mortality risk, Cox proportional hazards regression model was used to estimate the hazard ratios (HRs) and corresponding 95% CIs, while controlling for other confounders. Time from cancer diagnosis to hospice entry and length of hospice stay were skewed right, so were analysed using LIFEREG with a gamma error distribution with right censoring for not enrolled in hospice for time to hospice enrolment and if a patient died in hospice for length of stay in hospice.
The adjusted relationship between risk factors and outcomes was estimated using coefficients from these models, and exponentiated to yield a percentage change in the risk factor outcomes. A twosided P value <.05 was considered statistically significant. Statistical analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC).
3 | RESULTS
| Demographics of the study population
We received data on 31 149 patients with liver cancer who met the initial criteria specified in our data request. After applying our exclusion criteria, 2982 patients with primary liver cancer (HCC or ICC) remained in our final study cohort, and consisted of 1623 patients who had never enrolled in hospice (54%) and 1359 patients who had enrolled in hospice at least once (46%). The average age of the study cohort was 75. Of the entire study cohort, 63% were men, 65% were White, 89% resided in metropolitan neighbourhoods, and 19% had received radiation or surgical treatment. Overall, 
| Determinants of hospice enrolment
Compared to patients with liver cancer who never enrolled in hospice, patients who enrolled in hospice were on average 2 years older (74 vs 76 years old), more likely to be White (58% vs 75%), less critically ill as suggested by lower CCI (58% vs 51% had CCI ≥3), less likely to have decompensated liver cirrhosis (41% vs 34%), and were less likely to have undergone radiosurgery therapy (all P < .05) ( Table 1) .
Results of multivariate analysis on predictors for hospice enrolment are shown in 
| Mortality after the diagnosis of primary liver cancer
The average survival time after diagnosis of primary liver cancer was 5 months (IQR 2-15 months) for the nonhospice enrollees and 6 months (IQR 2-16 months) for the hospice enrollees (P = .189).
There was no significant difference in time from diagnosis to death (Table 1 ) or in one-year mortality (Table 2 ) between the two groups.
The multivariate-adjusted model for death within one year of diagnosis is illustrated in Table 2 and history of radiosurgery treatment were associated with longer time to hospice enrolment (Table 3) .
| Predictors of hospice length of stay
The average length of stay (LOS) in hospice was 14 days (IQR 9-20 days). The only variable associated with shorter stays in the hospice care was having unstaged primary liver cancer as compared to a localised tumour (Table 3 ).
| Predictors of resource utilisation
Hospitalisation occurred in approximately 70% of the cohort. While hospice enrollees had higher hospitalisation rates than nonhospice enrollees (73% vs 66%, P < .0001), they had less episodes of rehospitalisations (median total rehospitalisation 2 vs 3, P < .001) and lower median hospital charges (median (IQR), $22 316 ($13 741-$36 170) vs $ 31 607 ($18 394-$54 254), P < .0001) ( Table 1 ).
| DISCUSSION
In this study, we aimed to explore the determinants of hospice enrolment and report the impact of hospice care on survival among patients with primary liver cancer. As expected, our data showed that the overall prognosis of primary liver cancer is very poor. hospice have fewer rehospitalisation rates, but also their total annual hospital charges were almost 50% less than patients who did not enrol in hospice care. These findings are similar to previous studies which found that Medicare beneficiaries with poor-prognosis cancer who received hospice care had significantly lower rates of hospitalisation, intensive care unit admissions and invasive procedures at the end of life leading to lower total costs during the last year of life. 30 For example, in a recent study, investigators reported that patients with HCC enrolled in hospice were less likely to undergo hospitalisation or ICU stay, as well as less likely to die in the hospital than patients with HCC who never enrolled in hospice. 33 These findings are especially important as resource utilisation among Medicare patients with chronic liver disease is expected to increase. 34, 35 Studies demonstrated that at least a quarter of the general population has NAFLD, and NASH has been gaining increased recognition. 36 In fact, it is anticipated that there will be a rapidly increasing incidence of NASH-related HCC 37 and NASH will become the leading aetiology of HCC in the next 2 decades. 38, 39 In the light of these facts, the reduction in the hospital charges among patients enrolled in hospice care can be better appreciated.
Another interesting finding of our study was that the most significant area of disparity in the utilisation of hospice care among liver cancer patients was race. Specifically, non-White patients were significantly less likely to have enrolled in hospice, and Asian/Pacific
Islanders who did enrol in hospice did so significantly later after their diagnosis of HCC compared to Whites. Several previous studies have shown racial and ethnic disparities in palliative and hospice care. [40] [41] [42] This disparity has been suspected to be likely multifactorial, with possible aetiologies including distrust towards healthcare providers, difference in cultural beliefs about death that may conflict with the hospice philosophy, 41 language barriers, 43 lack of diversity among medical providers 40, 44 and differences in health literacy which can lead to misperception about hospice care. Of note, in our study, we did not see a significant association between hospice enrolment and other patient factors that have also been shown to be associated with low-health literacy such as low income 45 suggesting that health literacy may not be the main barrier driving the racial disparity in hospice care. A previous study also found that overall hospice use was higher in metropolitan than rural areas; however, in our analysis, there was no significant difference in hospice use based on residential area, suggesting that access to resources based on geographical
Never enrolled in hospice (n = 1623) Enrolled in hospice (n = 1359) P have been similar regional differences in practices that affect referral to hospice services, we were unable to define these factors in our study.
In summary, patients with primary liver cancer included in the SEER database have overall very poor prognosis, but a large proportion of these patients do not utilise hospice services despite the potential benefits. Our study showed that while enrolment in hospice care does not affect survival among liver cancer patients, embracing hospice earlier in the disease course and foregoing aggressive curative treatment does not decrease the time to death and may actually allow patients to live longer after diagnosis. In addition, hospice enrolment leads to decreased resource utilisation among patients with primary liver cancer. Future studies will need to focus on identifying the underlying reasons for the disparity in hospice enrolment, in order to provide appropriate support that allows for the delivery of hospice care and to effectively educate the public and medical community on the hospice philosophy in a timely manner.
